Radiopharm Theranostics (RADX) furnishes ASX Appendix 4E in Form 6-K

Rhea-AI Filing Summary

Radiopharm Theranostics Limited submitted a Form 6-K as a foreign private issuer to provide U.S. investors with information it released on the Australian Securities Exchange. The filing explains that the company published an announcement to the ASX on August 29, 2025 and attaches that disclosure as an exhibit. The exhibit, labeled 99.1, is the company’s Appendix 4E and preliminary final report. The company also notes that this Form 6-K, including the exhibit, is being furnished rather than filed under U.S. securities laws and will only be incorporated into other U.S. filings if specifically referenced.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 08/29/2025 - 08:34 AM Learn about SEC filing dates

FAQ

What did Radiopharm Theranostics (RADX) submit in this Form 6-K?

Radiopharm Theranostics Limited submitted a Form 6-K to furnish to U.S. investors an announcement it made to the Australian Securities Exchange, attaching that disclosure as an exhibit.

What is included as Exhibit 99.1 in RADX's Form 6-K?

Exhibit 99.1 to the Form 6-K is Radiopharm Theranostics Limiteds Appendix 4E and preliminary final report.

Is the information in this RADX Form 6-K considered filed under the Exchange Act?

The company states that this Form 6-K, including its exhibit, is being furnished and is not deemed to be filed for purposes of the U.S. Securities Exchange Act of 1934.

Will this Form 6-K be automatically incorporated into other RADX SEC filings?

No. The company notes that the Form 6-K and its exhibit will only be incorporated by reference into other U.S. securities filings if expressly set forth by specific reference.

Who signed the Form 6-K for Radiopharm Theranostics Limited?

The Form 6-K was signed on behalf of Radiopharm Theranostics Limited by Phillip Hains, the Company Secretary, dated August 29, 2025.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of August 2025

Commission File Number: 001-41621

RADIOPHARM THERANOSTICS LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐       No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

RADIOPHARM THERANOSTICS LIMITED

EXPLANATORY NOTE

Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on August 29, 2025 titled:

- “Appendix 4E and Preliminary Final Report”

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

1

EXHIBITS

Exhibit Number		Description
99.1		Appendix 4E and Preliminary Final Report

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	RADIOPHARM THERANOSTICS LIMITED
Date: August 29, 2025	By:	/s/ Phillip Hains
		Phillip Hains
		Company Secretary

3